29 results
8-K
EX-99.1
imnv11f5rl925q0o
8 Nov 22
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
8:41am
8-K
EX-99.1
5f8hz6e1mbp
19 Apr 21
Regulation FD Disclosure
4:22pm
8-K
EX-99.1
y15xmisqxn
9 Apr 21
Regulation FD Disclosure
10:01am
8-K
EX-99.1
cxjsx ly0
1 Dec 20
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
5:19pm